Replies to post #104094 on Biotech Values

[DewDiligence]

This should be a game changer tomorrow morning.

I doubt it. There was never any bona fide evidence that Sandoz was not taking a significant Lovenox share in the hospital setting, so Wheeler’s comment on today’s webcast, although bullish, is not exactly surprising.